share_log

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

Benzinga Real-time News ·  Sep 14, 2022 17:32
  • The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development ofTRACON's (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares traded as high as 5.26 percent, in a range of $1.9 to $2 on day volume of 111.77 thousand shares, closed regular trading session at $1.9.
  • Centessa Pharmaceuticals (NASDAQ:CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment